Pharma Mar
PHM.MCPharma Mar is a global leader in marine-based oncology drug discovery and development, leveraging its unique expertise in isolating and developing bioactive compounds from marine ecosystems. The company has successfully commercialized Yondelis® for soft tissue sarcoma and ovarian cancer, generating revenue to fund its robust clinical pipeline. Its strategic focus remains on advancing its portfolio of novel compounds, including lurbinectedin and PM54, through clinical trials for a range of difficult-to-treat cancers.
PHM.MC · Stock Price
Historical price data
AI Company Overview
Pharma Mar is a global leader in marine-based oncology drug discovery and development, leveraging its unique expertise in isolating and developing bioactive compounds from marine ecosystems. The company has successfully commercialized Yondelis® for soft tissue sarcoma and ovarian cancer, generating revenue to fund its robust clinical pipeline. Its strategic focus remains on advancing its portfolio of novel compounds, including lurbinectedin and PM54, through clinical trials for a range of difficult-to-treat cancers.
Technology Platform
Proprietary platform for the discovery and development of novel anticancer compounds derived from marine organisms, focusing on novel mechanisms of action related to transcription regulation and DNA damage response.
Pipeline
1| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Ferric carboxymaltose + ferrous glycine sulphate | Postoperative Anemia | Approved |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Pharma Mar competes with large oncology-focused pharma (e.g., Roche, AstraZeneca) and other biotechs in specific tumor types. Its primary differentiation is its unique marine-derived compound platform and the novel mechanism of action of its drugs, which target transcription in cancer cells, offering a potential advantage in treatment-resistant tumors.